Sign inJoin waitlistJoin the waitlist

Abhinav Sidana

Director, Prostate Cancer Focal Therapy · University of Chicago Medical Center

Credentials: · · · · · · ·

History

University of Chicago Medical Center
Present

National Cancer Institute
2016–2017
University of Cincinnati College of Medicine
2012–2016
University of Cinncinnati College of Medicine
2011–2012
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI
2003–2007

Research

Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus
European Urology · 2020 · 109 citations
Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal…
The Journal of Urology · 2018 · 91 citations
Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy
The Journal of Urology · 2017 · 89 citations

AG
Arvin George
22 papers · 12 as a resident
Peter Pinto
22 papers
BW
Brad Wood
19 papers
Peter Choyke
17 papers
Sadhna Verma
17 papers
Ismail Turkbey
16 papers
MM
Mahir Maruf
15 papers · 3 as a resident
Maria Merino
13 papers
Ardeshir Rastinehad
10 papers
Ronald Rodriguez
10 papers
Akhil Muthigi
9 papers · 7 as a resident
AJ
Amit Jain
8 papers · 8 as a resident

Clinical trials

PSMA PET for Surveillance After Focal Therapy
Principal investigator · Recruiting
University of Chicago
2025–2028
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Principal investigator · Recruiting · Phase 2
University of Chicago
2025–2028
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Principal investigator · Recruiting
University of Chicago
2024–2029
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027